Home Tags Pfizer
Dispensed: What to expect out of biotech M&A, Medicare Advantage enrollment in 2020, and what comes next for the DNA-testing industry
Welcome to Dispensed, Business Insider's weekly healthcare newsletter. This week, musings on the slowdown in genetics and dispatches from BIO.
The 30-stock index climbed 48 points higher to breach the psychological threshold, driven by gains in Pfizer, Apple, and Coca-Cola.
Dispensed: Hospital CIOs dish on the cloud, digital chiefs talk tech in healthcare, and how our editor picked his health plan
Welcome to Dispensed, our weekly dispatch of healthcare, biotech, and pharma news from Business Insider.
The new company will sell popular drugs such as Viagra, Lipitor, and Mylan's EpiPen, and is expected to generate around $20 billion in total sales.
The companies set to report earnings include big names like Apple, ExxonMobil, Berkshire Hathaway, and Verizon.
Allergan started out as a tiny but beloved Southern California eye care firm before expanding to a $130 billion company. Here’s how the Botox-ma...
Here's how Allergan went from its start as a sleepy but beloved company out of Southern California in the 1950s to an acquisition target for AbbVie.
Array BioPharma spikes more than 50% after Pfizer shells out $11 billion for the cancer-drug developer
Pfizer's blockbuster deal for Array BioPharma is the latest in a growing list of M&A deals to take place in the cancer-treatment space this year.
EpiPens weren’t working. It took 3 years and the FDA stepping in before serious change — with potentially deadly outcomes
Consumer complaints about EpiPens were increasing, but its manufacturer wasn’t properly looking into those complaints, FDA inspectors warned in 2014.
Drug giant Pfizer isn’t ready to abandon neuroscience — here’s its $150-million ‘star cluster’ strategy for betting on p...
Execs from pharma giant Pfizer shared their strategy for keeping an eye on neuroscience — if not from the front row, then at least from the sidelines.
Trump may have shamed Pfizer for increasing drug prices, but that isn’t stopping drugmakers from doing more of the same
Pharmaceutical companies are increasing drug price again this month, and they could be even larger than usual.